Dr. Aju Mathew, in this second part of the exclusive series on breast cancer for M3 India, writes on considerations that need to be employed for ovarian function suppression (OFS), a new adjuvant therapy, touted to be an effective treatment for breast cancer in young women.

For our comprehensive coverage and latest updates on COVID-19 click here.

In the first part of the series, I wrote about the various options to treat a young (premenopausal) woman with hormone-responsive breast cancer in an adjuvant anti-oestrogen setting. The key new advance in the field is the arrival of ovarian function suppression (OFS) as an adjuvant therapy. Several practice-changing trials have found that we can increase the cure rate for high-risk breast cancer when OFS is added as a treatment strategy.

OFS can be done primarily by two methods: